1. Abraham, R., Moller, D., Gabel, D., Senter, P., Hellstrom, I., and Hellstrom, K. E., 1991, The influence of periodate oxidation on monoclonal antibody avidity and immunoreactivity, J. Immunol. Meth. 144:77–86.
2. Adams, G. P., Mccartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. E., Bookman, M. A., Fand, I., Houston, L. L., and Weiner, L. M., 1993, Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv, Cancer Res. 53:4026–4034.
3. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G. T., Burke, R. J., Melton, R. G., and Sherwood, R. F., 1991, Antibody Directed Enzyme Prodrug Therapy (ADEPT)—Clinical Report. Dis. Marker 9;233–238.
4. Bagshawe, K. D., Springer, C. J., Searle, E, Antoniw, R, Sharma, S. K., Melton, R. G., and Sherwood, R. F., 1988, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58:700–703.
5. Bessos, H., Appleyard, C., Micklen, L. R., and Pepper, D. S., 1991, Monoclonal antibody leakage from gels: Effect of support, activation and eluant composition. Prep. Chromatogr. 1:207–220.